<DOC>
	<DOCNO>NCT00423371</DOCNO>
	<brief_summary>This multicenter , double-blind , randomize , parallel-group , active-controlled trial perform approximately 80 subject chronic idiopathic osteoarthritis ( OA ) first carpo-metacarpal joint ( CMC ) .</brief_summary>
	<brief_title>Double-Blind , Randomized , Placebo-Controlled Efficacy &amp; Safety Study EUFLEXXA™ Treatment OA First CMC</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>1 . Men woman ≥40 year age 2 . Pain due primary OA first CMC joint present least half day previous month AND mean combine pain score ≥ 30 mm 100 mm 5 pain question AUSCAN Index Pain Subscale ( See Appendix 1 ) 3 . A series Xrays confirm OA first CMC joint target thumb obtain screen stage 2 , 3 , 4 accord Grading Scale Appendix 3 . 4 . Ability willingness use acetaminophen analgesic ( rescue ) study medication The acetaminophen dose must exceed 4 grams/day ( 4000 mg ) If subject know chronic liver disease , maximum dose acetaminophen must exceed 2 grams/day ( 2000 mg ) The subject must willing able discontinue acetaminophen least 24 hour prior studyspecific visit The study specific acetaminophen provide used thumb/joint pain . 5 . Willingness ability complete efficacy safety questionnaires ability read understand study instruction 6 . Signed studyspecific Subject Informed Consent Form 1 . Any major injury target thumb within 6 month prior Screening Visit 2 . Anyone Carpal Tunnel Syndrome ( CTS ) , DeQuervain 's tenosynovitis , trigger finger , ganglion cyst target hand ONLY IF evidence extreme atrophy AND twopoint average discrimination great 10mm , OR pain condition render subject unable objectively assess OA pain target hand 3 . Any surgery target joint within 12 month prior Screening Visit 4 . Regular use assistive device cane crutch CTS brace 5 . Concomitant rheumatic disease ( rheumatoid arthritis , lupus arthropathy , psoriatic arthritis ) 6 . History chondrocalcinosis target joint 7 . Gout exacerbation joint past 6 month 8 . Xray finding acute fracture , severe loss bone density , and/or severe bone joint deformity target joint 9 . Significant target joint infection skin disorder/infection within 3 month prior study enrollment 10 . Known hypersensitivity acetaminophen , EUFLEXXA™ , Phosphate Buffered Saline solution 11 . Women childbearing potential pregnant , nursing , plan become pregnant , agree remain acceptable method birth control throughout entire study period 12 . Recurrent medical history severe allergic immunemediated reaction immune disorder 13 . Current treatment treatment within previous 2 year prior Screening Visit malignancy unless specific write permission provide Sponsor ( exclude basal cell squamous cell carcinoma skin ) 14 . Active liver disease base liver profile AST , ALT , conjugate bilirubin &gt; 2 time upper limit normal 15 . Renal insufficiency base serum creatinine &gt; 2.0 mg/dL 16 . Any clinically significant laboratory value base clinical history Investigator feel may affect study evaluation 17 . Any intercurrent chronic disease condition may interfere completion 6month followup study , liver disease , severe coronary disease , drug abuse , disorder mental state , clinically significant condition 18 . Current alcoholism , and/or know current addiction pain medication 19 . Any clinically significant find would place subject health risk , impact study , affect completion study 20 . Any psychiatric illness would prevent comprehension detail nature study 21 . Participation experimental device study within 6 month prior Screening Visit , experimental drug study within 1 month prior Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>first Carpometacarpal ( CMC ) Joint</keyword>
</DOC>